Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
2(14%)
Results Posted
17%(2 trials)

Phase Distribution

Ph phase_3
1
7%
Ph not_applicable
2
14%
Ph phase_2
1
7%
Ph phase_4
8
57%
Ph phase_1
2
14%

Phase Distribution

2

Early Stage

1

Mid Stage

9

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
1(7.1%)
Phase 3Large-scale testing
1(7.1%)
Phase 4Post-market surveillance
8(57.1%)
N/ANon-phased studies
2(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

12 of 12 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

14

all time

Status Distribution
Active(2)
Completed(12)

Detailed Status

Completed12
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
14
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 21 (7.1%)
Phase 31 (7.1%)
Phase 48 (57.1%)
N/A2 (14.3%)

Trials by Status

recruiting214%
completed1286%

Recent Activity

2 active trials
Showing 5 of 14
completedphase_1

A Study of Modified mRNA Vaccines in Healthy Adults

NCT05397223
recruitingphase_4

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

NCT04101838
recruitingphase_2

Systems Investigation of Vaccine Responses in Aging and Frailty

NCT05291676
completedphase_1

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
completedphase_4

Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children

NCT02871206
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT05397223Phase 1

A Study of Modified mRNA Vaccines in Healthy Adults

Completed
NCT04101838Phase 4

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Recruiting
NCT05291676Phase 2

Systems Investigation of Vaccine Responses in Aging and Frailty

Recruiting
NCT03312699Phase 1

Effects of Aging on Primary and Secondary Vaccine Responses

Completed
NCT02871206Phase 4

Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children

Completed
NCT02523287Phase 4

Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses

Completed
NCT04077424Phase 4

Senescent Immunity in Elders and Vaccine Responses (SILVER)

Completed
NCT03183908Phase 4

FLUAD® vs. Fluzone® High-Dose Study

Completed
NCT02686398Phase 4

Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis

Completed
NCT02368327Not Applicable

Gene Expression Profiles in Muscle After Immunisation

Completed
NCT01368796Phase 4

Comparison of 4 Influenza Vaccines in Seniors

Completed
NCT02215863Phase 4

Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years

Completed
NCT01771367Not Applicable

Training Study to Characterize Biomarkers to Flu Vaccines

Completed
NCT01032395Phase 3

Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

Completed

All 14 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
14